1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Bryan Schneider, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer Capecitabine, Talazoparib, Pembrolizumab - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Terminated | Bryan Schneider, MD | 52 | 2021-08-24 | 2025-05-31 |
| Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer Genomically Directed Monotherapy, Observation/Standard Therapy - Malignant Neoplasm of Breast, Breast Cancer | Phase 2 | Completed | Bryan Schneider, MD | 193 | 2014-04-03 | 2023-09-28 |
Breast Neoplasms (2) · Triple Negative Breast Neoplasms (1)
Capecitabine (1) · Observation (1) · Standard of Care (1) · inavolisib (1) · pembrolizumab (1) · talazoparib (1)
United States (2)
Bryan P Schneider, MD (1) · Bryan Schneider, M.D. (1)